Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force
Davide Angioni, Julien Delrieu, Oskar Hansson, Howard Fillit, Paul Aisen, Jeffrey L. Cummings, John R. Sims, Joel B. Braunstein, Marwan N. Sabbagh, T. Bittner, Michael J. Pontecorvo, Sasha Bozeat, Jeffrey L. Dage, Emily A. Largent, Soeren Mattke, O. Correa, Laura Robledo, V. Baldivieso, Deanna Willis, Alireza Atri, Randall J. Bateman, P-J. Ousset, Bruno Vellas, Michael W. Weiner
Abstract
Timely and accurate diagnosis of Alzheimer's disease (AD) in clinical practice remains challenging. PET and CSF biomarkers are the most widely used biomarkers to aid diagnosis in clinical research but present limitations for clinical practice (i.e., cost, accessibility). Emerging blood-based markers have the potential to be accurate, cost-effective, and easily accessible for widespread clinical use, and could facilitate timely diagnosis. The EU/US CTAD Task Force met in May 2022 in a virtual meeting to discuss pathways to implementation of blood-based markers in clinical practice. Specifically, the CTAD Task Force assessed: the state-of-art for blood-based markers, the current use of blood-based markers in clinical trials, the potential use of blood-based markers in clinical practice, the current challenges with blood-based markers, and the next steps needed for broader adoption in clinical practice.